Biogen cuts the price tag on its Alzheimer's drug in half

by Tom MurphyThe Biogen Inc., headquarters is shown March 11, 2020, in Cambridge, Mass. Biogen is slashing the price of its Alzheimer's treatment months after the drug debuted to widespread critic

Updated on: April 25,2024

Biogen cuts the price tag on its Alzheimer's drug in half

by Tom MurphyThe Biogen Inc., headquarters is shown March 11, 2020, in Cambridge, Mass. Biogen is slashing the price of its Alzheimer's treatment months after the drug debuted to widespread critic

Updated on:April 25,2024

FDA approves first drug meant to ease Alzheimer's-linked agitation

by Cara MurezA medication to treat agitation in Alzheimer's patients now has approval from the U.S. Food and Drug Administration.The FDA gave supplemental approval to Otsuka Pharmaceutical Company

Updated on: March 30,2024

FDA approves first drug meant to ease Alzheimer's-linked agitation

by Cara MurezA medication to treat agitation in Alzheimer's patients now has approval from the U.S. Food and Drug Administration.The FDA gave supplemental approval to Otsuka Pharmaceutical Company

Updated on:March 30,2024

Link found between chronic inflammation and risk for Alzheimer's disease

by Boston University School of MedicineWhile it is widely shown that possessing the ApoE4 gene is the major genetic risk factor of Alzheimer's disease (AD), not all ApoE4 carriers develop AD.

Updated on: March 07,2024

Link found between chronic inflammation and risk for Alzheimer's disease

by Boston University School of MedicineWhile it is widely shown that possessing the ApoE4 gene is the major genetic risk factor of Alzheimer's disease (AD), not all ApoE4 carriers develop AD.

Updated on:March 07,2024

Successful Phase 2 clinical trial for neflamapimod in mild-to-moderate Lewy body dementia

by University of North Carolina at Chapel Hill School of MedicineCredit: CC0 Public DomainEIP Pharma announced on October 6 that a phase 2 study in patients with mild-to-moderate Lewy body dement

Updated on: April 01,2024

Successful Phase 2 clinical trial for neflamapimod in mild-to-moderate Lewy body dementia

by University of North Carolina at Chapel Hill School of MedicineCredit: CC0 Public DomainEIP Pharma announced on October 6 that a phase 2 study in patients with mild-to-moderate Lewy body dement

Updated on:April 01,2024

Immune exhaustion in myalgic encephalomyelitis/chronic fatigue syndrome and long COVID

byGriffith UniversityCredit: Griffith UniversityUnlocking the secrets behind immune exhaustion in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and long COVID patients is at the ce

Updated on: November 13,2024

Immune exhaustion in myalgic encephalomyelitis/chronic fatigue syndrome and long COVID

byGriffith UniversityCredit: Griffith UniversityUnlocking the secrets behind immune exhaustion in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and long COVID patients is at the ce

Updated on:November 13,2024

Poor neighborhoods linked to elevated dementia risk and faster brain aging

by Duke UniversityCredit: CC0 Public DomainLiving in a poorer neighborhood is linked to accelerated brain aging and increased dementia risk early in life, regardless of income level or education,

Updated on: March 19,2024

Poor neighborhoods linked to elevated dementia risk and faster brain aging

by Duke UniversityCredit: CC0 Public DomainLiving in a poorer neighborhood is linked to accelerated brain aging and increased dementia risk early in life, regardless of income level or education,

Updated on:March 19,2024

Tardive dyskinesia impacts patients and caregivers

by Lori SolomonTardive dyskinesia (TD) poses a substantial burden for both caregivers and patients, according to a study published online Nov. 28 in theJournal of Patient-Reported Outcomes.Rakes

Updated on: February 03,2024

Tardive dyskinesia impacts patients and caregivers

by Lori SolomonTardive dyskinesia (TD) poses a substantial burden for both caregivers and patients, according to a study published online Nov. 28 in theJournal of Patient-Reported Outcomes.Rakes

Updated on:February 03,2024

Dementia leading cause of death in September

by Alzheimer's Research UKCredit: CC0 Public DomainThe Office for National Statistics (ONS) has today (23 October) revealed "dementia and Alzheimer's disease" were the leading c

Updated on: May 11,2024

Dementia leading cause of death in September

by Alzheimer's Research UKCredit: CC0 Public DomainThe Office for National Statistics (ONS) has today (23 October) revealed "dementia and Alzheimer's disease" were the leading c

Updated on:May 11,2024

COVID-19: Advice for caring for people with Alzheimer's disease, mild cognitive impairment

by From Mayo Clinic News NetworkCredit: CC0 Public DomainWith the COVID-19 pandemic at the forefront of daily life, how much information should you share with a loved one who has Alzheimer's disea

Updated on: March 26,2024

COVID-19: Advice for caring for people with Alzheimer's disease, mild cognitive impairment

by From Mayo Clinic News NetworkCredit: CC0 Public DomainWith the COVID-19 pandemic at the forefront of daily life, how much information should you share with a loved one who has Alzheimer's disea

Updated on:March 26,2024

Can phototherapy improve cognitive function in patients with dementia?

by WileyCredit: Pixabay/CC0 Public DomainIn an analysis of published clinical trials, investigators found that phototherapy—or exposure to sessions of bright light—may be a promising non-pharmaco

Updated on: June 05,2024

Can phototherapy improve cognitive function in patients with dementia?

by WileyCredit: Pixabay/CC0 Public DomainIn an analysis of published clinical trials, investigators found that phototherapy—or exposure to sessions of bright light—may be a promising non-pharmaco

Updated on:June 05,2024

Physical models of a patient's brain help researchers treat neurological disorders and diseases

by David Pulgar,Virginia Commonwealth UniversityRavi Hadimani, Ph.D., associate professor of mechanical and nuclear engineering, leads a team of researchers who seek to use TMS to excite or inhi

Updated on: February 05,2024

Physical models of a patient's brain help researchers treat neurological disorders and diseases

by David Pulgar,Virginia Commonwealth UniversityRavi Hadimani, Ph.D., associate professor of mechanical and nuclear engineering, leads a team of researchers who seek to use TMS to excite or inhi

Updated on:February 05,2024

BACE-Inhibitor successfully tested in Alzheimer's animal model

by Technical University MunichMarc Aurel Busche at the two-photon microscope, which allows to visualize nerve cells with high temporal and spatial resolution in the intact brain. Credit: Kurt Bau

Updated on: March 19,2024

BACE-Inhibitor successfully tested in Alzheimer's animal model

by Technical University MunichMarc Aurel Busche at the two-photon microscope, which allows to visualize nerve cells with high temporal and spatial resolution in the intact brain. Credit: Kurt Bau

Updated on:March 19,2024